Massive study checks if PCV20 vaccine stops pneumonia in At-Risk adults

NCT ID NCT07251465

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at health records of over 800,000 adults to see if the PCV20 vaccine reduces pneumonia cases. Researchers will compare pneumonia rates in people who got the vaccine versus those who did not. The goal is to measure how effective PCV20 is in adults aged 18 and older with conditions that raise their risk for pneumococcal disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PCV20 vaccine

What this could lead to

If effective, this could confirm that PCV20 helps prevent pneumonia in adults with higher risk, supporting its wider use.

What could go wrong

This is an observational study using existing records, not a controlled trial. Results may be affected by unmeasured differences between vaccinated and unvaccinated groups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory tract infectious disorder pneumonia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pfizer

    New York, New York, 10001, United States